Outcomes of Wound Healing in Patients with Diabetic Kidney Disease Undergoing SGLT2 Inhibitor Treatment
Overview
This study evaluates wound healing outcomes in patients with diabetic kidney disease (DKD) treated with SGLT2 inhibitors. The findings indicate no significant differences in wound healing time or infection rates compared to controls, while also preserving renal function over six months.
Background
SGLT2 inhibitors are recognized for their cardiorenal benefits in diabetic kidney disease, yet concerns about their safety in patients with active wounds persist. Understanding the impact of these medications on wound healing is crucial, as many eligible patients may be denied these therapies due to fears of impaired healing or increased infection risk.
Data Highlights
Outcome
SGLT2 Inhibitors
Controls
p-value
Median Healing Time (days)
33 (IQR: 22–52)
34 (IQR: 24–62)
0.594
Infection Rate
38.2%
32.4%
0.310
Renal Progression Events
0%
5.9%
0.029
eGFR Change (mL/min/1.73m²)
−2.3 ± 3.8
−5.5 ± 4.5
<0.001
Key Findings
No significant difference in median healing time between SGLT2 inhibitor users and controls (33 vs. 34 days).
Infection rates were similar between groups (38.2% vs. 32.4%).
No renal progression events occurred in the SGLT2 inhibitor group during the six-month follow-up.
SGLT2 inhibitor users demonstrated superior eGFR preservation compared to controls.
These findings suggest SGLT2 inhibitors do not impair wound healing in patients with DKD.
Clinical Implications
Clinicians can consider the use of SGLT2 inhibitors in patients with diabetic kidney disease and active wounds without significant concerns regarding impaired wound healing or increased infection risk. The preservation of renal function in these patients further supports the use of these agents.
Conclusion
The study provides evidence that SGLT2 inhibitors do not adversely affect wound healing in patients with diabetic kidney disease, while also offering renal protective benefits.
